Revenue Breakdown
Composition ()
No data
Revenue Streams
Standard BioTools Inc (LAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 44.5% of total sales, equivalent to $8.71M. Other significant revenue streams include Services and other revenue and Instruments. Understanding this composition is critical for investors evaluating how LAB navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Standard BioTools Inc maintains a gross margin of 47.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -92.09%, while the net margin is 58.42%. These profitability ratios, combined with a Return on Equity (ROE) of -13.13%, provide a clear picture of how effectively LAB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LAB competes directly with industry leaders such as MYGN and ORGO. With a market capitalization of $423.02M, it holds a significant position in the sector. When comparing efficiency, LAB's gross margin of 47.83% stands against MYGN's 69.97% and ORGO's 77.87%. Such benchmarking helps identify whether Standard BioTools Inc is trading at a premium or discount relative to its financial performance.
